Needham & Co Upgrades Cepheid (CPHD) to Buy
More News related to CPHD
- Cepheid to Webcast Upcoming Financial Presentations
- Cepheid (CPHD) Tops Q3 EPS Views; Guides
- Cepheid Reports 2009 Third Quarter Results
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Unusual 11 Mid-Day Movers 10/14: CHIO, ACPW, JADE, CNO Higher; CXM, HILL, UCBH, UPI Lower
Needham & Co upgrades Cepheid (Nasdaq: CPHD) from Hold to Buy. Price target $17.
To see more analyst ratings on CPHD Click Here.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.
Related Categories
UpgradesStocks Mentioned
+0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
